Gallium-68 EVG321 - Evergreen Theragnostics
Latest Information Update: 08 Jun 2024
At a glance
- Originator Innsbruck Medical University
- Developer Evergreen Theragnostics; Innsbruck Medical University
- Class Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Small cell lung cancer
Most Recent Events
- 21 May 2024 Evergreen Theragnostics enters into licensing agreement for the clinical development of EVG 321 for small cell lung cancer
- 21 May 2024 Early research in Small cell lung cancer (Diagnosis) in USA (Parenteral) prior to May 2024
- 21 May 2024 Evergreen Theragnotics plans registration enabling therapeutic clinical trials for Gallium-68 (68Ga) EVG321